Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy

摘要: Abstract Objectives The aim of this study was to assess the impact ticagrelor dosing regimens on pharmacodynamic (PD) profiles in patients maintenance therapy. Background Many P2Y12-inhibiting therapies may require coronary revascularization procedures, raising a common clinical question with regard regimen agent be used. To date, investigations assessing P2Y12 receptor inhibitors therapy have been only assessed thienopyridines, but not ticagrelor. Methods This prospective, randomized, double-blind, placebo-controlled PD effects 2 dosing standard aspirin and A total 60 were randomized either 90 mg (maintenance dose [MD] group) or 180 (loading [LD] assessments conducted at 3 time points (baseline, 1 h 4 h). defined according platelet reactivity index (PRI) (vasodilator-stimulated phosphoprotein phosphorylation assay), reaction unit (VerifyNow assay) adenosine diphosphate–induced aggregation by light transmittance aggregometry. Results There no differences baseline levels all assays. Intergroup comparisons means repeated-measures analysis adjusted for PRI values showed that LD group had significantly lower PRI compared MD during overall course (p = 0.031). Consistent findings were found unit 0.026) aggregometry 0.004). Intragroup more prompt sustained inhibitory effect achieved consistently an regimen. Conclusions In therapy, 180-mg is associated potent inhibition 90-mg MD. (Impact Ticagrelor Re-Load Pharmacodynamic Profiles; NCT01731041 ).